Ira Chatman, MD
Pain Medicine · Mountain Home, ARNPI 1922073014
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Boston Scientific at 31.5% of the total. Reporting peaked in 2019 at $822 and has fallen 85.5% since, to $119 in 2025. That places this record below the midpoint for pain medicine clinicians in AR, where the typical reported total is $3,271.
Across 79 payments — averaging $24.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$621
- Abbott$569
- Vertos Medical, Inc.$263
- Daiichi Sankyo Inc.$71
- Globus Medical$61
- Baudax Bio Inc.$57
- plus $331 from 13 others
What the payments were for
- Food & beverage$1,974100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 18 | $621 |
| Abbott | 28 | $569 |
| Vertos Medical, Inc. | 3 | $263 |
| Daiichi Sankyo Inc. | 5 | $71 |
| Globus Medical | 2 | $61 |
| Baudax Bio Inc. | 3 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Pfizer | 4 | $47 |
| SPR Therapeutics, Inc | 1 | $36 |
| Collegium Pharmaceutical, Inc. | 2 | $35 |
| Nevro Corp. | 1 | $27 |
| Orexo US, Inc. | 1 | $21 |
| Braeburn Inc. | 1 | $20 |
| Medtronic | 1 | $20 |
| Nalu Medical, Inc. | 1 | $18 |
| Stimwave Technologies Incorporated | 2 | $17 |
| Shionogi Inc | 1 | $15 |
| Midsouth Orthopedics Inc. | 1 | $15 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- mild Device Kit$128
How this compares
$1,974 in reported general payments places this provider in the 35th percentile of 53 pain medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 173 | $113,013 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 662 | $112,130 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 98 | $62,639 |
| OxycontinOxycodone Hcl | 105 | $60,588 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 2,404 | $56,034 |
| MovantikNaloxegol Oxalate | 112 | $46,134 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,481 | $42,900 |
| Morphine Sulfate ErMorphine Sulfate | 1,217 | $37,172 |
| Oxycodone Hcl | 1,889 | $34,735 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 60 | $31,441 |
| LinzessLinaclotide | 41 | $22,094 |
| NucyntaTapentadol Hcl | 14 | $17,367 |
| Gabapentin | 952 | $10,388 |
| BelbucaBuprenorphine Hcl | 16 | $9,736 |
| Buprenorphine | 38 | $9,438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta, Belbuca | $35 | $140,117203 claims |
| Orexo US, Inc.Zubsolv | $21 | $62,63998 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 53 pain medicine providers in Arkansas.
Other pain medicine in Mountain Home
- Maria Lyuksyutova-PriceMountain Home$19K
- Bryan SlepickaMountain Home$9K
- Matthew McNelleyMountain Home$5K
- Stephen PaulusLittle Rock$75K
- Mark MiedemaFayetteville$35K
- George ArcosConway$30K
- George DeimelFayetteville$26K
- Julio OlayaLittle Rock$22K
- Daniel JudkinsConway$17K
- Sheffield KentConway$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.